ASCO 2024 - Wrap Up: Myelodysplastic Syndrome

At the ASCO 2024 Annual Meeting, researchers presented the differences in time toxicity among patients undergoing myelodysplastic syndromes/neoplasms with oral hypomethylating versus parenteral hypomethylating agents. Read More ›

Wrap-Up

Phase 2 Results From the ASTREON Trial: Preliminary Safety and Efficacy of Oral AZA in Patients With Low-/Intermediate-Risk MDS

At the ASCO 2024 Annual Meeting, researchers presented oral azacitidine’s safety and efficacy results in patients with low-/intermediate-risk myelodysplastic syndromes, as documented in the ASTREON trial. Read More ›

Wrap-Up

Latest Results of a Phase 2 Study of IMM01 Combined With AZA: First-Line Treatment in Adults With HRMDS

ASCO 2024 - Wrap Up: Myelodysplastic Syndrome

At the ASCO 2024 Annual Meeting, researchers summarized the most recent results from the phase 2 study of IMM01 in combination with azacitidine, a first-line treatment for adults with higher-risk myelodysplastic syndromes. Read More ›

Wrap-Up

Efficacy of Luspatercept for the Treatment of Transfusion-Dependent, Erythropoiesis-Stimulating Agent–Naïve Patients With Very Low-, Low-, or Intermediate-Risk MDS in the COMMANDS Trial

ASCO 2024 - Wrap Up: Myelodysplastic Syndrome

At the 2024 ASCO Annual Meeting, researchers’ data from the COMMANDS trial, which evaluated the effectiveness of luspatercept in treating patients with transfusion-dependent, erythropoiesis-stimulating agent–naïve individuals with very low-, low-, or intermediate-risk myelodysplastic syndromes. Read More ›